Successful trial for Isentress compared to atazanavir and darunavir for treatment naive HIV - Merck Inc.

In a new 96-week, open-label AIDS Clinical Trials Group (ACTG) study designed to compare three different NNRTI-sparing HIV regimens in treatment-na�ve patients � one containing Merck�s twice-daily Isentress (raltegravir) and two containing different once-daily ritonavir-boosted protease inhibitors, atazanavir and darunavir -- all three regimens achieved high and equivalent levels of efficacy, as measured by time to virologic failure (VF), the study�s co-primary endpoint. On the other co-primary endpoint of failure due to tolerability, the Isentress and darunavir/r regimens were superior to the atazanavir/r regimen. In addition, on the key secondary endpoint of the combination of VF and tolerability failure (TF), the regimen with Isentress as superior to both of the protease inhibitor regimens. The results of this ACTG study were presented in an oral session at the 21st Conference on Retroviruses and Opportunistic Infections (CROI).